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Campylobacter jejuni remains a major cause of bacterial diarrhea worldwide and is asso-
ciated with numerous sequelae, including Guillain Barré Syndrome, inﬂammatory bowel
disease, reactive arthritis, and irritable bowel syndrome. C. jejuni is unusual for an intesti-
nal pathogen in its ability to coat its surface with a polysaccharide capsule (CPS). These
capsular polysaccharides vary in sugar composition and linkage, especially those involving
heptoses of unusual conﬁguration and O-methyl phosphoramidate linkages.This structural
diversity is consistent with CPS being the major serodeterminant of the Penner scheme,
of which there are 47 C. jejuni serotypes. Both CPS expression and expression of modi-
ﬁcations are subject to phase variation by slip strand mismatch repair. Although capsules
are virulence factors for other pathogens, the role of CPS in C. jejuni disease has not been
well deﬁned beyond descriptive studies demonstrating a role in serum resistance and for
diarrhea in a ferret model of disease. However, perhaps the most compelling evidence for
a role in pathogenesis are data that CPS conjugate vaccines protect against diarrheal dis-
ease in non-human primates. A CPS conjugate vaccine approach against this pathogen is
intriguing, but several questions need to be addressed, including the valency of CPS types
required for an effective vaccine.There have been numerous studies of prevalence of CPS
serotypes in the developed world, but few studies from developing countries where the
disease incidence is higher. The complexity and cost of Penner serotyping has limited its
usefulness, and a recently developed multiplex PCR method for determination of capsule
type offers the potential of a more rapid and affordable method. Comparative studies have
shown a strong correlation of the two methods and studies are beginning to ascertain
CPS-type distribution worldwide, as well as examination of correlation of severity of illness
with speciﬁc CPS types.
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INTRODUCTION
Campylobacter jejuni, one of the most common causes of bacter-
ial diarrhea worldwide, is biologically distinct from other enteric
pathogens, such as Salmonella, Shigella, and Vibrio. A member
of the epsilon proteobacteria, C. jejuni is more similar to Gram
negative mucosal pathogens such as Haemophilus inﬂuenzae and
Neisseria meningitidis in that it is microaerophilic, naturally trans-
formable, and encapsulated. The polysaccharide capsule (CPS),
which is the topic of this review, is unique for an enteric pathogen,
and the C. jejuni capsular polysaccharides are unique compared
to most others.
CAMPYLOBACTER CAPSULES: STRUCTURES AND GENETICS
During the 1990s,Aspinall and co-workers discovered thatCampy-
lobacter species (C. jejuni, C. coli, and C. lari) exposed polysac-
charides (PSs) that were considered to be O-chain PS regions
of cell-wall lipopolysaccharides (LPSs; Aspinall et al., 1992, 1993,
1995a,b; McDonald, 1993; Aspinall, 1998). However, structural
data obtained from someCampylobacter species showed that these
moieties were not associated with a LPS component, but were
of the same type as teichoic acid PSs, as in C. jejuni serotype
HS1 (for Heat Stable serotype; McDonald, 1993) and capsule
PSs (CPSs), as in C. lari (Aspinall, 1998). Subsequently, genomic
analysis provided conﬁrmation that the observed PSs of C. jejuni
were capsule (CPSs; Parkhill et al., 2000). Corcoran et al. (2006)
demonstrated the phospholipid anchor in three CPS types (HS3,
HS6, and HS23/36) was dipalmitoyl-glycerophosphate, with ester-
linked hexadecanoic acids.Campylobacter species, like otherGram
negative mucosal pathogens and unlike other enteric pathogens,
express a CPS and lipooligosaccharide (LOS; core→ lipid A) in
lieu of a full length LPS (O-chain→ core→ lipid A). The Pen-
ner serotyping scheme is a passive slide hemagglutination that
is based primarily on CPSs, although other structures, including
LOS can contribute to serotype speciﬁcity (Penner and Hennessy,
1980; Preston and Penner, 1989; Karlyshev et al., 2000). A total
of 23 serotypes were initially described in the original publication
(Penner and Hennessy, 1980), and this was quickly extended to
47 serotypes for C. jejuni, although many are found in related,
cross-reacting complexes.
The structure of eight CPS types of C. jejuni have been pub-
lished (Aspinall et al., 1992, 1995c; Hannify et al., 1999; Muldoon
et al., 2002;Karlyshev et al., 2005;McNally et al., 2005,2007;Gilbert
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et al., 2007; Chen et al., 2008), and these vary in sugar composition
and linkage. The expression of (i) heptoses of unusual conﬁgura-
tion (i.e., altro, ido, gulo, talo) and (ii) O-methyl phosphoramidate
(MeOPN) are key structural markers of the capsules of Campy-
lobacter species, especially C. jejuni (Figure 1). The structural
complexity of the heptoses is further enhanced by the introduc-
tion of a deoxy function at the C-6 position, in that, within a single
CPS polysaccharide chain, it is common to observe the presence of
the heptose and its complementary 6-deoxy-heptose, for example,
d-glycero-d-altro-heptose and 6-deoxy-altro-heptose in C. jejuni
strains that belong to serotype complex HS23/36 (Aspinall et al.,
1993; Kanipes et al., 2006). MeOPN has been identiﬁed on most
C. jejuni CPSs, although it is found attached in different linkages
to different sugars in each (Karlyshev et al., 2005; McNally et al.,
2007).MeOPN is also found innon-stoichiometric amounts, likely
because of phase variation (see below).
Campylobacter jejuni capsules are assembled via an ABC trans-
porter mechanism, similar to class 2 and class 3 capsules of E.
FIGURE 1 | Covalent structure of the CPS from C. jejuni strain 81–176
(serotype HS23/36).The trisaccharide repeating block is composed of
→3)-D-Galp-(1→2)-3-Me-6d-α-D-altro-Hepp-(1→3)-β-D-GlcpNAc-(1→ .
The methylated heptose is sometimes substituted by
6-deoxy-altro-heptose. The O-methyl phosphoramidate side chain is
connected to the C-2 position of Gal in non-stoichiometric amounts
(Kanipes et al., 2006).
coli K1 and K5, N. meningitidis and H. inﬂuenzae, and the genetic
organization of capsule genes in C. jejuni is similar to those found
in these bacteria, as shown in Figure 2. Capsule genes in these
groups are organized in three regions,where the conserved regions
1 and 3 are involved in capsule assembly and transport, and the
variable region 2 encodes genes responsible for synthesis of the
polysaccharides. The major difference between CPS groups 2 and
3 is the organization of the kps genes, and the presence of an
additional gene involved in thermoregulation of capsule synthe-
sis, kpsU, in group 2 capsule strains. C. jejuni is more similar to
the group 3 capsules by its absence of the kpsU gene and appar-
ent lack of thermoregulation (Stintzi, 2003), but appears to be a
hybrid between groups 2 and 3 due to differences in gene orga-
nization (Figure 2). Although the kpsM gene of 81–176 has been
shown to functionally complement the corresponding mutation
in E. coli K1 (Bacon et al., 2001), no functional studies of C. jejuni
kps gene products have been reported. The function of the prod-
ucts of Class 2 and Class 3 kps genes have been reviewed recently
(Vimr and Steenbergen, 2009).
Region 2, located between kpsC and kpsF in C. jejuni, contains
genes that are responsible for biosynthesis of speciﬁc polysaccha-
rides (see Figure 3). Variability of this region reﬂects the array
of CPS structures/Penner serotypes of C. jejuni. A total of 18
CPS loci from distinct Penner types have been sequenced to date
(Parkhill et al., 2000; Pearson et al., 2004; Fouts et al., 2005; Karly-
shev et al., 2005; Poly et al., 2011). Region 2 in these strains
contains from 11 to 30 genes and ranges in size to from 11 to
34 kb. Variation in this region reﬂects horizontal gene transfer,
gene duplication, deletion, and fusion, all of which participate in
the observed variability of CPS structures (Karlyshev et al., 2005).
Despite the high level of overall variability in region 2, some genes
are highly conserved. These include genes for synthesis of heptose
(hddC, gmhA, hddA) and deoxyheptose (dmhA) as well of genes
involves inMeOPNbiosynthesis.McNally et al. (2007) showed that
four genes (CJ1415c–1418c) are required for MeOPN synthesis in
NCTC 11168, and these genes are highly conserved in most strains
of C. jejuni. Two other genes, Cj1419c and Cj1420c, annotated as
methyl transferases, are always found adjacent to the MeOPN syn-
thesis genes, although a function has not been ascribed to them.
Figure 2 indicates that 61.5% (8/13) of published CPS loci contain
homologs of Cj1415c–Cj1420c. BLAST analysis reveals the pres-
ence of these genes not just in C. jejuni strains, but also in other
FIGURE 2 | Schematic of the capsule regions of E. coli group 2 and group 3 capsules compared to C. jejuni.
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FIGURE 3 | Schematic of variable region 2 CPS loci from sequenced representative Penner serotype loci.The function or putative function of genes is
color-coded, as indicated.
epsilon proteobacteria, including other species of Campylobacter,
Wolinella succinogenes, and Helicobacter spp. other than H. pylori.
Production of CPS in those strains in uncertain, but the high
degree of protein identity and gene order of the homologs sug-
gests a common source of origin (lateral transfer) of those genes
as well as a putative biosynthesis of MeOPN by a wider number of
species than originally thought (McNally et al., 2007).
McNally et al. (2007) also identiﬁed two genes adjacent to the
MeOPNgene cluster,Cj1421c andCj1422c, as transferases respon-
sible for addition of MeOPN to two distinct sites in the CPS of an
HS2 CPS (the C-3 of β-d-GalfNAc and to the C-4 of d-glycero-
α-l-gluco-heptopyranose residues). Based on similarity to these
MeOPN transferases, other putative MeOPN transferases can be
identiﬁed in additional C. jejuni CPS loci, all of which appear
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to be adjacent to the MeOPN biosynthesis genes. These puta-
tive MeOPN transferases contain a conserved N-terminal region
sequence and a variable C-terminal region. The conserved region
likely encodes the region of the enzyme that recognizes MeOPN,
while the variable region likely reﬂects the different sugar residues
to which MeOPN is attached.
The genes encoding enzymes for biosynthesis of heptose and
deoxyheptose are also highly conserved in various CPS loci.
CPS heptoses are synthesized by the products of hddC (putative
d-glycero-d-manno-heptose 1-phosphate guanosyltransferase),
gmhA2 (phosphoheptose isomerase),hddA (putative d-glycero-d-
manno-heptose 7-phosphate kinase). Biosynthesis of deoxyhep-
tose has been demonstrated in C. jejuni (Karlyshev et al., 2005)
and linked by homology of sequence to dmhA a putative GDP-
mannose 4,6-dehydratase involves in the conversion of heptose to
deoxyheptose. The enzymatic properties of DmhA from strain 81
to 176 were recently characterized (McCallum et al., 2011).
REGULATION OF CPS EXPRESSION
The ability of C. jejuni to undergo phase variations by slip strand
mispairing during replication at homopolymeric tracts of bases
is well established (Linton et al., 2000; Guerry et al., 2001; Hen-
drixson, 2006). C. jejuni CPS expression undergoes phase variable
changes at two levels. Expressionof CPSundergoes anon/off phase
variation, likely due to slip strand mismatching in one or more
genes in region 1 and 3 (Bacon et al., 2001; Guerry and Szymanski,
2008). Other phase variations can modulate the CPS structure.
Thus, GC tracts are commonly found in dmhA, Cj1420c (one
of the genes adjacent to the MeOPN genes, see above), as well
as putative MeOPN transferases. Thus, phase variable changes in
dmhA may regulate the amount of deoxyheptoses in the capsules
of HS23/36 complex, and changes in the MeOPN transferases are
thought to be responsible for the non-stoichiometric amounts of
this modiﬁcation on the CPS.
There is also some evidence that CPS expression is regu-
lated transcriptionally. Experimental determination of the tran-
scriptional patterns of the capsule genes has not been reported,
but in silico studies by Petersen et al. (2003) suggested a rpoD
(sigma70)-regulated operon that started with kpsM and extended
into region 2. Transcriptional proﬁling studies have suggested that
some of the genes involved in CPS biosynthesis are regulated
differentially. Thus, four genes in region 2 were reported to be
up-regulated under growth conditions with high iron (Palyada
et al., 2004), and some CPS genes in both region 2 and region 3
were down regulated in vivo in the stomach of pigs (Reid et al.,
2008). In vitro studies showed that four genes involved in CPS
transport and three genes involved in polysaccharide biosynthesis
were down regulated when C. jejuni was grown in the presence
of HCT-8 human intestinal epithelial cells (Corcionivoschi et al.,
2009). The signiﬁcance of these changes to capsule structure and
virulence remain to be determined.
ROLE OF CAPSULES IN VIRULENCE
The ability to turn CPS expression on and off suggests that CPS
expression may be advantageous at some points during the C.
jejuni lifestyle and disadvantageous at others, suggesting a role
in virulence. Similarly, the ability to phase vary the structure of
the CPS, such as modifying the levels of MeOPN, likely serves a
biological purpose. Polysaccharide capsules are important in vir-
ulence for virtually all bacteria that express these structures, but
surprisingly little is understood about the role that CPS plays in C.
jejuni-mediated disease. Bacon et al. (2001) showed that a kpsM
mutant of strain 81–176 showed a modest (about 10-fold) reduc-
tion in invasion of intestinal epithelial cells in vitro. Similar results
were obtained using non-encapsulated mutants of other strains by
Bachtiar et al. (2007) and Corcionivoschi et al. (2009). The latter
study also demonstrated that capsule expression by both 81–176
and NCTC 11168 was reduced by passage with HCT-8 intestinal
cells in culture, as mentioned above. This result was somewhat
unexpected, but the passaged cells showed reduced invasion that
correlatedwith reduced capsule expression.However, the passaged
cells represented those not attached to the monolayer; the authors
did not examine capsule expression on adhered or invaded cells.
There have been a few studies that have examined the inter-
action of the C. jejuni CPS with various components of the host
innate immune response. C. jejuni shows levels of resistance to
complement killing that are comparable to those of other mucosal
pathogens, and, like othermucosal pathogens, the CPS contributes
to resistance to complement killing (Bacon et al., 2001; Keo et al.,
2011). However, it is not clear if complement resistance is required
for intestinal colonization or after invasion of the intestinal epithe-
lium. Zilbauer et al. (2005) showed that C. jejuni 81–176 and
NCTC 11168 induced human β-defensins 2 and 3 (hBD2 and
hBD3) from intestinal epithelial cells in culture, but that both
wildtype and kpsM mutants of both strains were equally sensitive
to the action of these β-defensins. This is consistent with work of
Keo et al. (2011) who showed that the LOS core played a role in
resistance to β-defensins and polymyxin, but that the CPS played
a limited role. In contrast, capsules on other mucosal pathogens
have been shown to protect against β-defensins (Campos et al.,
2004). Rose et al. (2011) showed that non-encapsulated mutants
showed increased production of IL-6, IL-10, and TNF-alpha from
murine dendritic cells. A similar effect was seen with mutant that
lacked MeOPN on the capsule, suggesting an important biological
role for this unusual modiﬁcation.
There are limited small animal models for C. jejuni disease.
Champion et al. (2010) have developed a model using the larvae
of the wax moth, Galleria mellonella. Injection of three differ-
ent strains of C. jejuni into the larvae resulted in rapid killing.
Using speciﬁc mutants the authors showed that the polysaccharide
CPS of strain NCTC 11168, and speciﬁcally, the MeOPN modi-
ﬁcation, was responsible for this lethality. This may be related to
the fact the MeOPN is structurally related to organophosphorus
pesticides, but the signiﬁcance of this ﬁnding to human disease
remains to be determined. Chickens, which can become colonized
with C. jejuni without disease, have been used to study commen-
salism. Two groups have shown that encapsulated strains colonize
chickens better than unencapsulated mutants (Grant et al., 2005;
Bachtiar et al., 2007). Unfortunately, there are few diarrhea models
of disease for C. jejuni, but Bacon et al. (2001) showed that a kpsM
mutant of 81–176 was attenuated in diarrheal disease in an infant
ferret model. More convincing evidence of a role in diarrheal dis-
ease has come from vaccination studies in non-human primates
(see below).
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THE BURDEN OF C. JEJUNI DISEASE
Campylobacter jejuni infection, which occurs through exposure to
contaminated food and water, is a major global health problem. In
the developingworld it is estimated that 40–60%of children under
the age 5 will develop at least one symptomatic infection, usually
occurring during the ﬁrst year of life (reviewed in Coker et al.,
2002). Epidemiologic studies are lacking in geographically diverse
settings, but those that do exist suggest that repeated pediatric
infections are not uncommon. Recent data suggest that Campy-
lobacter may be even more important than previously thought.
The Global Enterics Multi-Center Study (GEMS), a prospective,
multi-center, case–control study of acute diarrhea in children
0–59months of age funded by the Bill and Melinda Gates Foun-
dation, has found in 2-year follow-up data that Campylobacter
infections in Asia (Bangladesh, India, Pakistan) represent impor-
tant enteric infections leading to severe diarrhea in the ﬁrst years
of life (Levine, 2011). A recent passive clinical surveillance study
in a deﬁned catchment population from Karachi, Pakistan reports
an annual incidence of C. jejuni infection of 29 per 1,000 person-
years, with peak incidence at around 2 years of age (Sooﬁ et al.,
2011). It is notable that C. jejuni infections were more frequently
diagnosed than Shigella, though Shigella was more often associ-
ated with dysentery. Additionally, for the developing world, one
must consider the association between Campylobacter and HIV
infection where incidence may be increased, and morbidity and
mortality are found to be higher among HIV positive individ-
uals (Sorvillo et al., 1991; Molina et al., 1995; Tee and Mijch,
1998). In a case series of 38 patients with HIV and Campylobacter
infection, acute diarrhea, fever, and abdominal painwas a predom-
inant symptom complex, however 11% had bacteremia, and 8%
experienced chronic diarrhea (Molina et al., 1995). Furthermore,
long-term carriage of Campylobacter can occur, sometimes asso-
ciated with recurrent attacks of enteritis and bacteremia among
HIV infected individuals. Given the growing HIV pandemic, it
is estimated that the burden of campylobacteriosis in developing
countries may be among the top 10 in 2020.
In the industrialized world, general population incidence esti-
mates based on passive surveillance vary depending on geography
and over time with rates in the US averaging around 15/100,000
with a slow decline over the past decade, and rates in Europe
around 50–90/100,000 with rising trends (reviewed in Janssen
et al., 2008). Some countries in Eastern Europe and New Zealand
have higher incidence rates of 300–400/100,000 per year. Due
to underreporting of these types of illness, true rates of campy-
lobacteriosis are considered to be 10–100 times higher than those
reported historically. To this end, recent population-based studies
in a number of developed countries have employed varied study
designs to estimate overall incidence of Campylobacter infections
through use of cohort studies, state of the art and standardized
identiﬁcation methods, surveys, and active surveillance networks
(Table 1). These studies conﬁrm the underreporting and case
ascertainment bias associated with passive surveillance studies and
ﬁnd that incidence of Campylobacter infection ranges from 3 to
15 cases per 1,000 person-years.
Finally, travelers represent unique populations that are at high
risk for Campylobacter, where globally it occurs in 5–15% of
diarrheal cases (Riddle et al., 2006; Shah et al., 2009). Campy-
lobacter infections are considerably more frequent in some areas
of SE Asia. Ravel et al. (2011) recently reported data from an
enhanced, passive surveillance system of travel-related diseases
caused by enteropathogens within a Canadian community from
June 2005 to May 2009. Of the 446 cases of travel-related disease
Table 1 | Global estimates of Campylobacter incidence in developed countries.
Reference Kubota et al. (2008) Tam et al. (2012) DeWit et al. (2001) Hall et al. (2008) Scallan et al. (2011)
Country Japan UK Netherlands Australia US
Year of study 2006–2007 2008–2009 1998–1999 2000–2004 2006
Study design Two 2-week
cross-sectional,
population-based
telephone surveys
combined with
catchment area
surveillance
Prospective,
community cohort
study and prospective
study of general
practice presentation in
national surveillance
system
Prospective
population-based
study with nested
case–control
study in general
population
Empirical model
based on published
and unpublished
data from multiple
active/passive
surveillance sources
Empirical model based
on published and unpub-
lished data from mul-
tiple active/passive sur-
veillance sources
Numbers 4,247 Household
interviews, 8,462
laboratory conﬁrmed
cases ascertained in
active surveillance
6,836 Cohort
participants, 800,000
catchment area for
national surveillance
4,860 Patients
enrolled in cohort
Not applicable Not applicable
Incidence
estimate (95%
CI), per 1,000
person-years
15.1 (7.4–28.6) 10.9 (7.4–15.9) 4.8 (1.7–10.4) 11.8 (7.6–26.7) 2.8 (not given)
Foodborne illness
rank
1 of 3 overall 4 of 12 overall; 1 of 5
bacterial
1 of 5 bacterial 1 of 3 overall 4 of 31 overall; 3 of 21
bacterial
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due to enteropathogens reported, Campylobacter was the most
frequently identiﬁed cause (n = 123, 28%). Similarly, in a report
from the GeoSentinel Travel Network, a clinician-based sentinel
surveillance data for 17,353 ill returned travelers, Campylobacter
was identiﬁed in 8.5 per 100 diarrheal cases and was the leading
bacterial etiology (Freedman et al., 2006).
Taken together, these data highlight the clear importance of
Campylobacter in global populations in terms of disease incidence,
but do not completely portray the enormity of Campylobacter
as a public health problem. An increasing number of studies
are highlightingCampylobacter-associated chronic health sequelae
(Table 2). Beyond the well described association with Guillain–
Barré Syndrome (GBS), the leading cause of acute ﬂaccid paralysis
in the developing world for which up to a third can be attributed
to Campylobacter, reactive arthritis, inﬂammatory bowel disease
(particularly Crohn’s Disease), and irritable bowel syndrome are
also recognized as post-campylobacteriosis sequelae in industrial-
ized populations, although there is lack of information on these
sequelae in the developing world. Furthermore, it will be of inter-
est to explore possible associations with CPS type as well as other
virulent mechanisms and these health sequelae.
From a public health perspective, some country-level
approaches have been attempted to quantify and characterize the
burden and cost associated with acute diarrheal infections and
their chronic consequences. For example, in New Zealand it is
estimated that major foodborne illness and its chronic health con-
sequences costs society approximately $86 million per year, and
90% of this cost is attributed to lost productivity due to absence
from work (Lake et al., 2010), and campylobacteriosis is shown to
account for approximately 90% of the estimated cost of foodborne
illness. Cost and burden of disease studies in Australia and the
Netherlands have also been conducted outlining substantial indi-
vidual and societal costs in which acute disease is either matched
or exceeded by the chronic consequences (Mangen et al., 2004).
Beyond the country-level perspective focusing on domestically
acquired foodborne infections, populations at high risk for acute
infectious diarrhea (e.g., travelers, military) should also be con-
sidered in estimating the full burden of disease and the potential
value of current and novel interventions. It should be noted, while
not as well studied, the chronic consequences of Campylobacter
infections in developing world populations should not be under-
estimated. Given the known mucosal barrier disruption effects of
Campylobacter infection (Beltinger et al., 2008), the contribution
of this particular infection may emerge as an important factor
to malnutrition and associated consequences in the developing
world. An international group of investigators are collaborating
on a project entitled The Interactions of Malnutrition and Enteric
Infections (MAL–ED): Consequences for Child Health and Devel-
opment (http://mal-ed.fnih.org/), involving a network of eight
sites that are exploring the factors associated with a child’s risk
of enteric infection, chronic diarrhea, malnutrition, as well with
impaired gut function, vaccine response, and cognitive and phys-
ical development (Lorntz et al., 2006; Tarleton et al., 2006; Santos
et al., 2008; Oria et al., 2010). Given the known mucosal barrier
disruption effects of Campylobacter infection, it will be important
to follow.
While more study utilizing improved diagnostics and charac-
terizing the pathogenesis of acute and chronic health effects of
Campylobacter infections is needed, the data that is available sug-
gest that control of Campylobacter should be considered a global
public health priority. Promotion and strengthening of food safety
systems, goodmanufacturing practices and educating retailers and
consumers about appropriate food handling and avoiding conta-
mination are needed now and can be employed. Education of con-
sumers and training of food handlers in safe food handling is one
of the most critical interventions in the prevention of foodborne
illnesses. Due to the challenges of implementing these aforemen-
tioned strategies, however, vaccines for use in travelers, military
personnel, and pediatric populations in the developing world are
much needed. To this end, we have explored the feasibility of CPS
conjugate vaccines against C. jejuni.
CPS CONJUGATE VACCINES AS A STRATEGY AGAINST C.
JEJUNI
CPS-based vaccine strategies have been very successful at reduc-
ing the overall disease incidence of several encapsulated bacte-
ria including Streptococcus pneumoniae, N. meningitidis, and H.
inﬂuenzae (reviewed in Lesinski andWesternick, 2001a;Knuf et al.,
Table 2 | Summary evidence of post-Campylobacter infection risk of select chronic health consequences.
Sequelae Post-infective
attributable risk*
Comment Reference
Guillain Barré syndrome 1 per 1,000 14–32% of GBS cases can be attributed to C. jejuni Nachamkin et al. (2000)
Reactive arthritis 1–5% 5% of C. jejuni ReA may be chronic or relapsing Pope et al. (2007)
Inﬂammatory bowel
disease
3–4 per 10,000 Recent evidence suggests that C. jejuni can breach the intestinal
barrier and may prime the intestine for chronic inﬂammatory
responses in susceptible individuals (Kalischuk and Buret, 2010)
Gradel et al. (2009), Jess et al.
(2011), Rodriguez et al. (2006)
Irritable bowel
syndrome
1–10% IBS developed in 36% of patients associated with a large
waterborne outbreak of mixed Campylobacter and STEC in
Walkerton, Canada. Symptoms persist in approximately 40–50%
at 5–7 years
Rodriguez and Ruigomez (1999),
Thornley et al. (2001), Dunlop et al.
(2003), Marshall et al. (2006)
*Post-infective attributable risk considers the absolute difference of the rate of sequelae after C. jejuni compared to the rate of the sequelae in an unexposed
population.
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2011). Given the success of these capsular-based vaccines, we have
begun studies to determine the feasibility of a capsule conjugate
vaccine approach to prevent disease caused by C. jejuni.
Most capsular polysaccharides are thymus-independent (TI)
antigens meaning that helper T cells are needed to generate robust,
long-lived antibody responses. Although adults can generate some
antibody responses to puriﬁed capsules administered as a vaccine
(Lesinski and Westernick, 2001b), children<2 years of age do not
develop strong responses to TI antigens (Rijkers et al., 1998). As
most carbohydrate antigens cannot directly activate naïve T cells,
a carrier protein is often included to optimize immune responses
(Knuf et al., 2011). This vaccine strategy effectively converts a TI
antigen into a thymus dependent (TD) antigen that allows boost-
ing of the immune response, IgG antibody class switching, and
the generation of memory cells possessing antibody with higher
avidity for CPS (Lesinski and Westernick, 2001b).
In the initial studies,CPSwas puriﬁed fromC. jejuni strains 81–
176 (HS23/36) and CG8486 (HS4 complex) and conjugated to the
carrier protein, CRM197, which is a mutant diphtheria toxin sub-
unit, using reductive amination (Monteiro et al., 2009). BALB/c
mice were immunized subcutaneously with escalating doses of
C. jejuni CPS–CRM197. Maximal titers were generated following
three doses of vaccine. One month after the last dose of vaccine,
immunized mice were challenged with each respective strain using
an intranasal infection model to determine if vaccination con-
ferred protection. Immunized mice exhibited signiﬁcantly lower
levels of sickness following challenge suggesting that antibodies
generated against the capsule afforded some protection against
infection with C. jejuni in this model. However, testing in a more
relevant model was still required.
The New World monkey, Aotus nancymaae, has been shown
to develop diarrheal disease that mimics aspects of human illness
following orogastric challenge with C. jejuni (Jones et al., 2006).
To determine if immunization with CPS–CRM197 could prevent
diarrheal disease, monkeys were immunized with 2.5μg of poly-
saccharide adjuvanted with alum three times with an interval of
6 weeks between subcutaneous injections. Nine weeks following
the third immunization, monkeys were challenge orogastrically
with approximately 1011 CFU of C. jejuni 81–176. The diarrheal
attack rate for non-immunized control monkeys was 70%. How-
ever, 100% of vaccinated animals (14/14) were protected against
diarrheal disease (Monteiro et al., 2009). This work was the ﬁrst
demonstration that a capsule conjugate vaccine could protect
against enteric disease and also suggests that the capsule plays
a critical role in virulence.
These proof-of-concept studies proved the feasibility of using
a capsule conjugate vaccine to prevent illness caused by C. jejuni.
However, before developing a vaccine for practical use, the number
of CPS types needed to achieve broad coverage against the most
prevalent strains of C. jejuni needs to be determined
CPS TYPING BY MULTIPLEX PCR
The likely target population for a vaccine against C. jejuni would
be civilian and military travelers to endemic regions and pedi-
atric populations living in endemic areas. However,while there are
extensive data on Penner types of C. jejuni strains from the devel-
oped world, particularly the Europe and Canada, there are limited
data from less developed countries (LDC) where the incidence of
C. jejuni diarrhea is high. Figure 4 summarizes published data
on Penner types from sporadic clinical cases based on >16,000
clinical isolates from the developed world and about 700 from
LDC. A non-systemic review of Penner typing for sporadic clin-
ical cases identiﬁed HS4, HS2, and HS1 as the most common
globally. The HS4 complex was the most prevalent, accounting for
21.2 and 13.2% of all cases for the developed and LDC, respec-
tively, followed by HS2 (16.4 and 7.96% for developed and LDC,
respectively) and the HS1 complex (10.7 and 6.81% for devel-
oped and LDC, respectively). Penner types HS3, HS5, and HS8
were also prevalent worldwide, while other serotypes tend to show
geographic and population-based variability. More than 10% of
isolates from the developed world and >21% from the develop-
ing world were non-typeable in the Penner scheme. This could
reﬂect the existence of CPS types not covered in the Penner typ-
ing scheme, but it is also in partly due to the fact that Penner
serotyping requires CPS expression and a certain percentage of
these isolates have turned capsule expression off by phase variation
(Poly, unpublished).
To overcome the limited data on CPS distribution in LDC’s, a
C. jejuni CPS multiplex-based PCR was recently developed and
validated. The current CPS multiplex is composed of a total of 14
primer pairs, separated into two mixes, alpha and beta (Poly et al.,
2011). Primers were designed on speciﬁc sequences of available C.
jejuni class 2 loci (Figure 2). Most of the Penner serotypes that
fall into related complexes are recognized with the same pair of
primers. Thus, the multiplex system does not distinguish between
HS23 and HS36 and other similar complexes of Penner types,
which have very similar CPS structures that crossreact immuno-
logically.Attribution of CPS type is deciphered based on the length
of the PCR product after electrophoresis on a 2% agarose gel
along with a molecular weight ladder. This technology was val-
idated on a total of 244 strains of known serotype and shown
to have sensitivities and speciﬁcities ranging from 90 to 100%.
A perfect correlation between CPS type and Penner type was
demonstrated. This technology is still expanding and is currently
being evaluated in multiple laboratories worldwide. One advan-
tage of the multiplex system over classical serotyping is that the
multiplex is independent of phase variation in capsule expres-
sion. Collection of additional data by the multiplex PCR will
provide a more accurate picture of C. jejuni CPS distribution,
particularly in LDCs, that will dictate the ﬁnal formulation of an
effective CPS conjugate vaccine. The ability to rapidly determine
capsule type will also facilitate studies to determine if speciﬁc
CPS types are associated with more severe acute diarrheal dis-
ease and with the chronic sequelae, particularly functional bowel
disorders.
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